The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; Immunome; Novartis; Sequenom; Trovagene
Research Funding - Agios; Astellas Pharma; BioMed Valley Discoveries; Deciphera; Fujifilm; Novartis; Piqur; Plexxikon; Roche; Symphony Evolution
Other Relationship - Bio-Rad
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Novartis; Pfizer
 
Vivek Khemka
Employment - Cancer Treament Centers of America
Research Funding - Acerta Pharma (Inst); AstraZeneca/MedImmune (Inst); Caris Centers of Excellence (Inst); Caris Life Sciences (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Jiangsu Hengrui Medicine (Inst); Plexxikon (Inst); Tesaro (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst)
 
Minny Bhatty
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
Jessica Tao
No Relationships to Disclose
 
Jonathan R. Whisenant
Research Funding - Merck
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Nam Bui
No Relationships to Disclose
 
Shivaani Kummar
Consulting or Advisory Role - Corvus Pharmaceuticals; MedTree (I); Nodus Therapeutics
Research Funding - ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Dynavax Technologies (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Pfizer (Inst); Plexxikon (Inst)
 
Lynn G. Feun
Research Funding - Merck Sharp & Dohme (Inst)
 
Aparna Raj Parikh
Employment - Genentech
 
Chao Zhang
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Glenn Michelson
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Eric Martin
Employment - Plexxikon
 
Rafe Shellooe
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Paul Severson
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Michael Pelayo
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
David Alan Karlin
Employment - Plexxikon
Consulting or Advisory Role - Apollo; Genentech; Orpheus Therapeutics; Plexxikon; Selecta Biosciences; Vivus
Patents, Royalties, Other Intellectual Property - Selecta Biosciences
 
Sunil Sharma
Stock and Other Ownership Interests - Beta Cat Pharmaceuticals; ConverGene; Proteus Digital Health; Salarius Pharmaceuticals; StiL Forschungs; Stingray Therapeutics
Honoraria - ARIAD; Array BioPharma; Blend Therapeutics; Exelixis; Foundation Medicine; Foundation Medicine; Genesis Biotechnology Group; Guardant Health; Guardant Health; Loxo; Novartis; Novartis; US Oncology
Consulting or Advisory Role - LSK BioPharma; Natera
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Onyx (Inst); Plexxikon (Inst); XuanZhu (Inst)
Patents, Royalties, Other Intellectual Property - Patent: “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.; Patent: Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.
Travel, Accommodations, Expenses - BioTherapeutics Delivery Society; Five Prime Therapeutics; HeritX; LSK Biopharma; LSK Biopharma; Translational Genomics Research Institute